Syros Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch SYRS and buy or sell other stocks, ETFs, and their options commission-free!

About SYRS

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. 

CEO
Nancy A. Simonian
CEONancy A. Simonian
Employees
124
Employees124
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2011
Founded2011
Employees
124
Employees124

SYRS Key Statistics

Market cap
25.20K
Market cap25.20K
Price-Earnings ratio
—
Price-Earnings ratio—
Dividend yield
—
Dividend yield—
Average volume
5.31M
Average volume5.31M
High today
—
High today—
Low today
—
Low today—
Open price
$0.0004
Open price$0.0004
Volume
0.00
Volume0.00
52 Week high
$5.22
52 Week high$5.22
52 Week low
$0.65
52 Week low$0.65

Stock Snapshot

With a market cap of 25.2K, Syros Pharmaceuticals(SYRS) trades at $0.00.

On 2026-10-28, Syros Pharmaceuticals(SYRS) shares started trading at $0.00, with intraday highs of — and lows of —.

Trading volume for Syros Pharmaceuticals(SYRS) stock has reached 0, versus its average volume of 5.31M.

The stock's 52-week range extends from a low of $0.65 to a high of $5.22.

The stock's 52-week range extends from a low of $0.65 to a high of $5.22.

People also own

Based on the portfolios of people who own SYRS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.